patrys is a leader in igm antibody development, page-8

Malmanu's statement ---
"Patrys has overcome this traditional hurdle by becoming the first in the industry with the ability to effectively manufacture and produce natural human IgM molecules at a commercial scale"
---may well hold the clue to where this is going. I think Patrys has patents in place covering this. What may well happen is that upon approval of the IgM treatment for use as a cure (successfull trialling on humans is the final precurser) that Patrys will go it alone and therefore at this time really don't want a suitor. Just a thought.